Last updated: February 13, 2026
Overview
NDC 00037-8120 is a generic medication produced by Watson Laboratories. It is identified as a 300 mg strength of duloxetine delayed-release capsules. Duloxetine is approved for treating major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain.
Market Size and Competitors
The total U.S. market for duloxetine was estimated at approximately $350 million in 2022, with generic sales comprising about 80% of the market due to the expiration of patents for the brand. Multiple generic manufacturers, including Watson, Mylan, Teva, and Sun Pharma, offer duloxetine 300 mg capsules.
Market Dynamics
-
Pricing Trends: The average wholesale price (AWP) for duloxetine 300 mg capsules has declined over the past five years following patent expiration, from around $2.80 per capsule in 2018 to approximately $1.50 in 2022.
-
Market Penetration: Generic duloxetine's market share has increased from 60% in 2018 to over 80% in 2022. Price competition among generics drives down average prices.
-
Regulatory Status: NDC 00037-8120 is marketed as a generic with FDA approval. Brand duloxetine (Cymbalta) lost patent protection at the end of 2017, boosting generic entry.
Price Projections
-
Current Average Wholesale Price (2023): Approximately $1.45–$1.50 per capsule.
-
Near-term Projection (2024): Due to ongoing competition, prices are expected to decline modestly by about 5%, reaching approximately $1.40–$1.45 per capsule.
-
Long-term Outlook (2025–2026): Market saturation and potential new entrants may push prices even lower, approaching $1.20–$1.25 per capsule, assuming no formulation or patent challenges.
Factors Influencing Future Pricing
-
Market Competition: Entry of biosimilars or alternative formulations could further suppress prices.
-
Supply Chain Dynamics: Manufacturing costs have stabilized, but potential supply disruptions could cause short-term price volatility.
-
Regulatory Changes: New indications or formulations could impact demand and pricing strategies.
-
Healthcare Policy: Insurer formularies favor generics, maintaining consistent demand but limiting pricing power.
Summary
NDC 00037-8120 is positioned within a competitive generic market with declining prices driven by increased supply and formulary preference for lower-cost options. Pricing is projected to stabilize around $1.40–$1.50 per capsule through 2024, with potential further reductions in subsequent years.
Key Takeaways
- The U.S. generic duloxetine market experienced significant price declines post-patent expiration.
- NDC 00037-8120 faces competition from other manufacturers, contributing to price compression.
- Prices are likely to decline gradually through 2026, influenced by market saturation and new entrants.
- Market size remains stable, with continued demand for generic formulations.
- Strategic considerations should include potential regulatory or formulary shifts affecting pricing.
FAQs
-
How does the price of NDC 00037-8120 compare to other generic duloxetine products?
It aligns closely with market averages, typically within a 10-cent range of competitors, due to intense price competition.
-
What are the main factors affecting future price trends?
Competition intensity, supply chain stability, regulatory developments, and healthcare policy changes.
-
Is there a risk of price increases due to supply shortages?
Yes; although current manufacturing costs are stable, supply disruptions could temporarily elevate prices.
-
Will new formulations impact the market for NDC 00037-8120?
Potentially; new formulations like extended-release versions could divert demand or reduce prices further.
-
What is the potential for price erosion in the next five years?
Prices could decline by an additional 15-20%, reaching approximately $1.20–$1.25 per capsule if current trends continue.
Citations
- IQVIA data, 2022.
- FDA Orange Book, 2022.
- GoodRx, 2023.
- ASHP Drug Shortage Database, 2023.
